Cognition enhancers for the treatment of dementia. - Wikidata - awgldk - TriplyDB

Cognition enhancers for the treatment of dementia.

Cognition enhancers for the treatment of dementia.

http://www.wikidata.org/entity/Q30872331

about

Behavioral alterations are associated with vitamin B12 deficiency in the transcobalamin receptor/CD320 KO mouse Pharmaceutical care services to people living with dementia in care homes: A qualitative study of community pharmacists' perceptions.

P2860

Q33703586-68CF3013-31D7-4FC4-AD69-F19041A280ED Q47563432-40C22EAE-2AB8-4351-8D53-711A34F50039

P2860

Cognition enhancers for the treatment of dementia.

http://www.wikidata.org/entity/Q30872331

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cognition enhancers for the treatment of dementia.

@ast

Cognition enhancers for the treatment of dementia.

@en

type

label

Cognition enhancers for the treatment of dementia.

@ast

Cognition enhancers for the treatment of dementia.

@en

prefLabel

Cognition enhancers for the treatment of dementia.

@ast

Cognition enhancers for the treatment of dementia.

@en

P1433

Q30872331-3455670B-9253-4553-97CA-7AB82B1EC7A5

P1476

Q30872331-9D668919-FAD8-44F8-9736-F6866D068031

P2093

Q30872331-5AAE74DD-4A08-4D9A-93BE-05429554E2E1

Q30872331-DD903032-1824-4141-A96D-48E1923A2135

P2860

Q30872331-13DE7A46-6D55-4399-8C38-F74153F5D229

Q30872331-1DB26A0B-06D5-4990-8338-6FA70EC42415

Q30872331-20D01D68-DA90-45E9-8151-1AC8CF82E9C8

Q30872331-28635384-EDD2-41C6-BD68-C621ACA446CA

Q30872331-30BF2336-9857-4C20-8BA4-C4E5349CB546

Q30872331-3D06FCB8-862B-41C2-9E76-EF0E98DCA651

Q30872331-4C19A4EC-20CD-44C7-A7A8-2924850DB385

Q30872331-4E58667B-AC60-4FE5-B444-EB6FF9150D78

Q30872331-6761180F-354A-4064-8E43-F1CD2FE2C69B

Q30872331-6A97BD17-660C-412B-868C-4B224ADB6969

P304

Q30872331-CF9211A5-F7B5-475A-97BA-EF785AB57935

P31

Q30872331-9FA49F77-CBE9-468C-9D47-70B905E782CB

P356

Q30872331-FBE2164D-3475-4184-9DB8-719B8C96654D

P433

Q30872331-F08B3924-F735-45B3-9AA3-5C85F55A61BF

P478

Q30872331-EBC48EEF-61BF-4B38-AA88-E1DC1D60FB71

P577

Q30872331-ACC34961-7C19-48D2-A7D0-452729CC13B8

P698

Q30872331-8CFE5D7B-368F-4026-B822-54D577C8BCE4

P356

0036933014561948

P1433

Scottish Medical Journal

P1476

Cognition enhancers for the treatment of dementia.

@en

P2093

John Greene

http://www.w3.org/2001/XMLSchema#string

Naveed Malek

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.

Cochrane review on 'Statins for the treatment of dementia'.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Acetylcholinesterase inhibitors: pharmacology and toxicology.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

P304

44-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0036933014561948

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25431454

http://www.w3.org/2001/XMLSchema#string